Unknown

Dataset Information

0

Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy.


ABSTRACT: Oncolytic virus (OV) therapy utilizes replication-competent viruses to kill cancer cells, leaving non-malignant cells unharmed. With the first U.S. Food and Drug Administration-approved OV, dozens of clinical trials ongoing, and an abundance of translational research in the field, OV therapy is poised to be one of the leading treatments for cancer. A number of recombinant OVs expressing a transgene for p53 (TP53) or another p53 family member (TP63 or TP73) were engineered with the goal of generating more potent OVs that function synergistically with host immunity and/or other therapies to reduce or eliminate tumor burden. Such transgenes have proven effective at improving OV therapies, and basic research has shown mechanisms of p53-mediated enhancement of OV therapy, provided optimized p53 transgenes, explored drug-OV combinational treatments, and challenged canonical roles for p53 in virus-host interactions and tumor suppression. This review summarizes studies combining p53 gene therapy with replication-competent OV therapy, reviews preclinical and clinical studies with replication-deficient gene therapy vectors expressing p53 transgene, examines how wild-type p53 and p53 modifications affect OV replication and anti-tumor effects of OV therapy, and explores future directions for rational design of OV therapy combined with p53 gene therapy.

SUBMITTER: Bressy C 

PROVIDER: S-EPMC5415316 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy.

Bressy Christian C   Hastie Eric E   Grdzelishvili Valery Z VZ  

Molecular therapy oncolytics 20170321


Oncolytic virus (OV) therapy utilizes replication-competent viruses to kill cancer cells, leaving non-malignant cells unharmed. With the first U.S. Food and Drug Administration-approved OV, dozens of clinical trials ongoing, and an abundance of translational research in the field, OV therapy is poised to be one of the leading treatments for cancer. A number of recombinant OVs expressing a transgene for p53 (TP53) or another p53 family member (TP63 or TP73) were engineered with the goal of genera  ...[more]

Similar Datasets

| S-EPMC4918398 | biostudies-literature
| S-EPMC4918378 | biostudies-literature
| S-EPMC8065251 | biostudies-literature
| S-EPMC5993491 | biostudies-literature
| S-EPMC5457316 | biostudies-literature
| S-EPMC5608221 | biostudies-literature
| S-EPMC7101593 | biostudies-literature
| S-EPMC9818137 | biostudies-literature
| S-EPMC8961675 | biostudies-literature
| S-EPMC309173 | biostudies-other